Iterum Therapeutics (ITRM) announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer, CCO. In this role, Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH in the United States, as well as future commercialization activities across new products and markets.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks